TY - JOUR T1 - Pembrolizumab <em>Versus</em> Combined Chemotherapy With Gemcitabine and Paclitaxel: A Comparative Assessment of Clinical Outcomes in Patients With Platinum-refractory Advanced Urothelial Cancer JF - In Vivo JO - In Vivo SP - 1889 LP - 1894 DO - 10.21873/invivo.12453 VL - 35 IS - 3 AU - AYANA TAKEMURA AU - YUTO MATSUSHITA AU - KEITA TAMURA AU - TAKAYUKI SUGIYAMA AU - MASAO NAGATA AU - ATSUSHI OTSUKA AU - HIDEAKI MIYAKE Y1 - 2021/05/01 UR - http://iv.iiarjournals.org/content/35/3/1889.abstract N2 - Background/Aim: There are limited data on comprehensive assessments of several treatments as second-line therapy against advanced urothelial cancer (UC). The objective of this study was to compare clinical outcomes between advanced UC patients receiving either pembrolizumab (Pem) or combined chemotherapy with gemcitabine and paclitaxel (GP) as second-line therapy. Patients and Methods: This study retrospectively analyzed the clinical outcomes of 89 patients with platinum-refractory advanced UC, consisting of 46 and 43 who received Pem and GP therapy, respectively, as second-line treatment. Results: There were no significant differences in major clinicopathological parameters between Pem and GP groups. No significant difference in the objective response rate was noted between the two groups. Progression-free survival (PFS) in the Pem group was significantly longer than that in the GP group; however, there was no significant difference in overall survival (OS) between them. Multivariate analyses identified performance status ≤2 and liver metastasis as independent factors associated with poor outcomes in both PFS and OS. The incidence of adverse events in the GP group was significantly higher than that in the Pem group. Conclusion: Pem could be regarded as standard agent for platinum-refractory advanced UC patients. ER -